Allurion Technologies

?? "Just eat less and move more"—many people living with obesity have heard this before. But sometimes, it's not that simple. Obesity is a complex, chronic disease, and for some, lifestyle changes alone may not be enough. Additional medical support can play a crucial role in achieving lasting, healthy weight loss. A 2021 study led by Dr. Raftopoulos (1) found that patients using the Allurion Balloon lost 2.4 times more weight compared to those relying solely on lifestyle changes. This highlights the importance of scientifically proven, non-invasive solutions to support those struggling with obesity. On World Obesity Day, let’s move beyond outdated advice and work towards better understanding, better treatments, and better support for people on their weight-loss journey. ?? What changes do you think are needed in how we approach obesity care? Let’s start the conversation. ?? #WorldObesityDay #ObesityCare #BeyondWillpower #AllurionBalloon #HealthForAll #ScienceBackedSolutions 1. Raftopoulos Y., et al. The Swallowable Gastric Balloon Significantly Enhances an Intensive Lifestyle Intervention Program for Weight Loss: Final Short and Long Term Results up to 1 Year after Balloon Placement. Presented at the virtual ASMBS, 2021.

?? Obesity is not just about weight. It’s about health, empowerment, and breaking down stigma. This #WorldObesityDay, we invite you to hear from six incredible women who courageously share their personal weight-loss journeys—from the Allurion Balloon to gastric sleeves and beyond. Their stories highlight: ? The reality of living with obesity—beyond stereotypes and societal judgments ? The fight against stigma—challenging misconceptions and reshaping mindsets ? What’s gained in losing—confidence, health, and a renewed sense of self. Obesity is a complex, chronic disease1, and overcoming it requires more than just willpower—it takes support, innovation, and access to the right solutions. ?? Watch the video and be inspired by their stories. Together, let’s change the narrative and build a healthier, more inclusive future. ?? Learn more: www.worldobesityday.org #WorldObesityDay #EndObesity #ChallengeObesityStigma #ChangingSystems #HealthierLives #Allurion #PatientFirst 1. According to the World Health Organization

?? Together, we can build a healthier future. Obesity is a complex, chronic disease (1), and like any health condition, we believe it requires patient-centered solutions—not a one-size-fits-all approach. At Allurion, we are proud to be?a leader of?innovation in obesity care, expanding treatment choices so that each person can find the solution that’s right for them. Because everyone’s journey is unique, and everyone deserves access to the care that works best for them. This #WorldObesityDay, let’s challenge outdated perceptions, advocate for better support, and work together to create a healthier, more inclusive future. ?? Join the movement: www.worldobesityday.org #ChangingSystems #HealthierLives #WorldObesityDay #EndObesity #Allurion #PatientFirst 1. According to the World Health Organisation

?? It's time to change the conversation about obesity. By 2035, 1 in 4 people will be living with obesity.* Yet, misconceptions still dominate public perception. We believe obesity is not about laziness, willpower, or personal choice—it is a complex, chronic disease that requires understanding, support, and systemic change. This #WorldObesityDay, let’s commit to creating a world where people living with obesity receive the care, respect, and holistic support they deserve. Together, we can make a difference. ?? ??? Watch the video and join the movement. #ObesityAwareness #WorldObesityDay #HealthForAll #SupportNotStigma * World_Obesity_Atlas_2023_Report.pdf

There is an "arms race" happening right now between Big Pharma and Big Food. Just as bacteria evolve to evade antibiotics, so too will Big Food to make junk food more addictive to offset the effects of GLP-1s. This, in turn, will lead Big Pharma to produce more potent GLP-1s that may have more significant side effects. Big Food and Big Pharma will emerge as winners from this arms race. The loser here is the consumer and the patient. Without a holistic solution focused on behavior change, any weight loss intervention (including GLP-1s), will not succeed in the long-run. Consumers and patients deserve better, and that is why we do what we do at Allurion Technologies!

Exciting News - Allurion Announced Last Month Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity We have the intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 agonists. The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy. Read more in our press release here - https://lnkd.in/eZq3ffgC

?? Procedureles Gastric Balloon: Evidence-Based Weight Loss A systematic review and meta-analysis published in Obesity Surgery evaluated 6 studies with 2,013 patients of the Allurion Program and demonstrated the efficacy and safety of the Allurion Balloon (1): ?? 12.75% Total Body Weight Loss (TBWL) at 4 months ?? 10.94% TBWL sustained at 1 year ?? Minimal adverse events: ?????2.3% balloon intolerance requiring removal ???? ?0.2% of serious adverse events These results support our belief that the Allurion Balloon 'is a reasonably safe device and could become a practical tool for weight loss' ? Discover how the Allurion Program is transforming lives through science-driven innovation. Learn more: (1) Vantanasiri, K., Matar, R., Beran, A., & Jaruvongvanich, V. (2020).

The future clinical pipeline for Allurion Technologies is taking shape with a focus on muscle mass and combination with GLP-1s to reduce side effects and long-term adherence. "...this could lead to multiple wins for patients, providers, and pharma: more patients with sustained weight loss, more longitudinal and profitable practices for providers, and higher long-term utilization of medication for pharma.” https://lnkd.in/eTQsxM6Y

?? Your Safety, Our Priority At Allurion, we are committed to ensuring your journey to weight loss is safe and supported every step of the way. The Allurion Program features continuous monitoring and guidance from experienced healthcare professionals, so you can achieve your goals with confidence. ????

We are back in France! Thrilled to announce today that ANSM, the French regulatory authority, has cleared Allurion Technologies to resume sales in France. I am looking forward to bringing the Allurion Balloon back to French patients at a time when the need for clinically proven treatments for obesity has never been higher. Onward! https://lnkd.in/eJ9Audr3